Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- MTPC Files Remicade for Kawasaki Disease
May 18, 2015
- Daiichi Sankyo Profit Quintuples on Gains from Ranbaxy-Sun Merger
May 15, 2015
- Eisai Earnings Pummeled by Generic Erosions in Japan, US
May 15, 2015
- Mitsubishi Chemical Group to Strengthen Presence in Field of Regenerative Medicine by Acquiring Clio Inc.
May 15, 2015
- Vital KSK Holdings Names Taisuke Murai as President
May 15, 2015
- Kyorin Holdings Names Minoru Hogawa as Next President
May 15, 2015
- Wider Indications Will Give Edge to Plavix AGs: Nichi-Iko Pres.
May 14, 2015
- Takeda Halts PIII Study of Aurora A Kinase Inhibitor for Peripheral T-cell Lymphoma
May 14, 2015
- Blopress AG Gives Lift to ASKA Sales and Profits
May 13, 2015
- Ono’s Operating Profit Declines 40%; NHI Price Reductions, Generics Had Major Negative Impact
May 13, 2015
- Ono to Expand Cancer-Specialized Rep Force to 150 by October Aiming for Additional Indications for Opdivo
May 13, 2015
- Denka Seiken to Start Development of Mass Production Technology for Therapeutic Oncolytic Virus for Cancer Therapy
May 13, 2015
- Ethical Drug Sales Down 5.2% in March: Crecon Report
May 13, 2015
- Shionogi Logs Record Ordinary Profit on Weaker Yen, ViiV Dividends
May 12, 2015
- Sumitomo Dainippon’s Profits Slide as Japan Sales Flounder
May 12, 2015
- Astellas Withdraws NDA for Nateglinide in Combination with DPP-4 Inhibitors
May 12, 2015
- Astellas Earnings Buoyant on Xtandi, Overseas Sales Offset Japan Fall
May 12, 2015
- MTPC Sees Sales Rise for Remicade in FY2015, Mulls M&A under 5-Year Biz Plan
May 11, 2015
- MTPC Sales Up Slightly as Gilenya, Invokana Royalties Eclipse Japan Dip
May 11, 2015
- Takeda, NCC Join Hands on Cancer Drug Research
May 11, 2015
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…